J. Willson

发表

Cost Effectiveness of Tiotropium in Patients with Asthma Poorly Controlled on Inhaled Glucocorticosteroids and Long-Acting β-Agonists

I. Pavord, E. Bateman, D. Esser, 2016, Applied Health Economics and Health Policy.

Recent real-world treatment patterns and outcomes in US patients with relapsed/refractory multiple myeloma

O. Lunacsek, J. Nelson, D. Stafkey-Mailey, 2020, Expert review of hematology.

DREAMM-2: Indirect Comparisons of Belantamab Mafodotin vs. Selinexor + Dexamethasone and Standard of Care Treatments in Relapsed/Refractory Multiple Myeloma

C. Hogea, A. Suvannasankha, V. Kapetanakis, 2021, Advances in Therapy.

Assessing the treatment pattern, health care resource utilisation, and economic burden of multiple myeloma in France using the Système National des Données de Santé (SNDS) database: a retrospective cohort study

L. Sansbury, S. Sapra, W. Sopwith, 2022, The European Journal of Health Economics.

Comparative effectiveness of mepolizumab and omalizumab in severe asthma: An indirect treatment comparison.

F. Albers, R. Alfonso-Cristancho, E. Bradford, 2017, Respiratory medicine.

Balancing work and family life : a study of mothers in the UK

J. Willson, 2010 .

Maternal movements to part time employment: what is the penalty?

J. Willson, 2010 .

Belantamab mafodotin for the treatment of relapsed/refractory multiple myeloma in heavily pretreated patients: a US cost-effectiveness analysis

C. Hogea, Y. Samyshkin, J. Tosh, 2021, Expert review of hematology.

Assessing the treatment pattern, health care resource utilisation, and economic burden of multiple myeloma in France using the Système National des Données de Santé (SNDS) database: a retrospective cohort study

L. Sansbury, S. Sapra, W. Sopwith, 2022, The European Journal of Health Economics.

Incidence of corneal adverse events in patients with multiple myeloma and their clinical and economic impact: A real-world retrospective cohort study

L. Sansbury, Chi-Chang Chen, S. Nunna, 2022, Journal of Medical Economics.